Non-surgical skin tightening is one of the most requested — and most oversold — categories in aesthetic medicine. The three most established platforms are Ultherapy (micro-focused ultrasound with visualization), Sofwave (planar ultrasound at the mid-dermis), and Thermage FLX (monopolar radiofrequency). All three stimulate collagen by heating tissue below the skin surface. None of them replicate what a surgical facelift does.
The honest framing is: these devices can improve the appearance of mild to moderate skin laxity. They do not lift the SMAS (superficial musculoaponeurotic system) the way surgery does — with one partial exception, Ultherapy, which targets the SMAS with focused ultrasound energy. How much that SMAS targeting translates into a clinically meaningful "lift" versus tighter-looking skin is where the evidence gets nuanced.
This article compares the three devices by mechanism, depth, FDA clearance language, comfort, cost, and the patients most likely and least likely to see a meaningful result.
The mechanism: ultrasound vs. radiofrequency
Ultrasound delivers acoustic energy that converges at a specific focal depth, creating a small thermal coagulation point. The tissue above and below the focal point is largely spared. Think of it like a magnifying glass focusing sunlight — the energy is concentrated at one specific layer.
Radiofrequency (RF) delivers electrical current that generates heat through tissue resistance. The heating is volumetric — it affects a broader volume of tissue rather than a precise focal point. RF heats a cylinder of tissue from the surface down to its maximum penetration depth.
The practical difference: ultrasound can target a specific depth with precision, which is why Ultherapy can aim at the SMAS layer. RF heats more broadly, which is why Thermage covers larger surface areas efficiently but cannot isolate a single tissue plane.
Ultherapy (Merz Aesthetics): micro-focused ultrasound with visualization
Manufacturer: Merz Aesthetics (Raleigh, NC / Frankfurt, Germany). Ultherapy was originally developed by Ulthera, Inc., which Merz acquired in 2014. The current platform is Ultherapy PRIME.
FDA clearance: Ultherapy received the first FDA De Novo classification (K072505) in 2009 for non-invasive brow lift. Subsequent clearances added neck and submental lift (2012), décolleté wrinkle improvement (2014), and — for Ultherapy PRIME in November 2025 — anterior arms, posterior arms, and abdomen. Ultherapy is the only non-surgical device with FDA clearance specifically for lifting (brow, submental, neck).
How it works: Ultherapy delivers micro-focused ultrasound (MFU-V) through interchangeable transducers at three depths: 1.5 mm (superficial dermis), 3.0 mm (deep dermis), and 4.5 mm (SMAS/fibromuscular layer). A key differentiator is the real-time ultrasound visualization (DeepSEE imaging on PRIME), which allows the provider to see the tissue layers before and during treatment and adjust energy placement accordingly.
What it targets: Brow laxity, submental (under-chin) fullness from skin sagging, neck skin laxity, décolleté wrinkles, and — with the 2025 clearance — arm and abdominal skin laxity.
Treatment time: 45–90 minutes for face/neck, depending on areas treated.
Discomfort: Moderate to high. Heating the SMAS layer to 60–65°C is inherently uncomfortable. Most patients describe a deep aching or burning sensation. Topical anesthetic and oral pain medication are commonly used. The discomfort is the main reason patients cite for not repeating the treatment.
Results timeline: 3–6 months for full collagen remodeling. Initial tightening may be visible within weeks as existing collagen contracts from the thermal injury, but the neocollagenesis response takes months.
Longevity: Manufacturer data suggests results last 12+ months on the face. Maintenance treatments are recommended annually. The 2025 arms/abdomen clearance notes results last 6+ months for body areas.
Cost: $2,500–$4,500 per session (face/neck). Body areas vary.
Evidence: Over 120 publications and 56 clinical studies cited by Merz. A systematic review published in PMC (2022) cataloged the clinical efficacy data for micro-focused ultrasound, noting that while efficacy is documented, the magnitude of improvement varies and depends heavily on patient selection and technique. A 2016 study by Werschler and Werschler in J Clin Aesthet Dermatol documented long-term efficacy of customized treatment.
Sofwave: synchronous ultrasound parallel beam
Manufacturer: Sofwave Medical Ltd (Yokneam, Israel). Sofwave is a newer entrant compared to Ultherapy and Thermage.
FDA clearance: Initial FDA 510(k) clearance (K211483, 2021) for improvement of facial lines and wrinkles, eyebrow lift, and submental/neck tissue lift. Subsequent clearances added cellulite (K232455, 2023), upper arm skin laxity (2023), acne scars (K241685, 2024), and — most recently — Pure Impact EMS for muscle toning (K250146, 2025).
How it works: Sofwave uses SUPERB (Synchronous Ultrasound Parallel Beam) technology, which delivers planar ultrasound energy at 1.5 mm depth in the mid-dermis. Unlike Ultherapy's focal point, Sofwave's energy spreads across a treatment zone — it creates a 3D array of volumetric thermal zones that heat the mid-dermis where fibroblasts are concentrated. An integrated cooling system (SofCool) protects the epidermis.
What it targets: Fine lines and wrinkles, mild skin laxity, eyebrow position, submental and neck laxity, acne scars, cellulite. The focus is on skin quality (collagen, elastin, hyaluronic acid stimulation) rather than deep structural lifting.
Treatment time: 30–45 minutes for face/neck.
Discomfort: Mild to moderate. Sofwave's superficial depth and integrated cooling make it significantly more comfortable than Ultherapy. Most patients describe brief warm pulses with each pass. Topical anesthetic is usually not required, though it can be used for sensitive patients.
Results timeline: Visible at 2–3 months post-treatment, with continued improvement through 6 months.
Longevity: Annual maintenance recommended.
Cost: $2,000–$4,000 per session (face/neck).
Evidence: Clinical data is growing but smaller than Ultherapy's body of literature. A 2024 FDA 510(k) submission (K240687) included clinical study results supporting safety and efficacy. As a newer platform, long-term data beyond 2–3 years is not yet available.
Thermage FLX (Solta Medical): monopolar radiofrequency
Manufacturer: Solta Medical (Bothell, WA), a division of Bausch Health. Thermage is the oldest platform of the three — the original Thermage received FDA clearance in 2002. The current generation is Thermage FLX.
FDA clearance: Thermage FLX received FDA 510(k) clearance (K170758, 2017) for non-invasive treatment of periorbital wrinkles and rhytids, general wrinkles and rhytids, and — with simultaneous vibration — temporary improvement in the appearance of cellulite. Thermage is cleared for wrinkle treatment and skin smoothing, not for "lifting."
How it works: Thermage delivers monopolar RF energy through a treatment tip against the skin. A return electrode pad is placed elsewhere on the body to complete the circuit. The RF current heats tissue volumetrically from the surface down to approximately 2.5–4.3 mm depth, depending on the tip used. AccuREP technology measures skin impedance and adjusts energy delivery with each pulse for consistency. A vibrating handpiece is integrated for patient comfort.
What it targets: Face, eyelids, neck, and body areas (abdomen, arms, thighs, knees) for skin tightening and wrinkle reduction. The broad volumetric heating makes it efficient for treating larger body areas.
Treatment time: 45–90 minutes for face; up to 2 hours for body areas.
Discomfort: Moderate. The volumetric heating creates a sensation of deep warmth that builds over the session. The vibration handpiece helps. Most patients tolerate it without anesthetic, but some request topical numbing.
Results timeline: Immediate collagen contraction provides some visible tightening right after treatment, with continued improvement over 2–6 months as new collagen forms.
Longevity: 1–2 years, depending on the patient's aging trajectory.
Cost: $1,500–$3,500 per session (face); $2,500–$5,000 for body areas.
Evidence: 20+ years of clinical use. Solta Medical cites 200+ peer-reviewed publications across its platforms (Thermage, Fraxel, Clear + Brilliant). A systematic review in PMC (2022) of micro-focused ultrasound noted that RF devices like Thermage provide tissue tightening through collagen denaturation but with less depth precision than ultrasound.
How they compare
| Ultherapy PRIME | Sofwave | Thermage FLX | |
|---|---|---|---|
| Energy type | Micro-focused ultrasound | Planar ultrasound | Monopolar RF |
| Depth | 1.5 / 3.0 / 4.5 mm | 1.5 mm | ~2.5–4.3 mm (volumetric) |
| Reaches SMAS | Yes (4.5 mm transducer) | No | No |
| Real-time imaging | Yes (DeepSEE) | No | No |
| FDA clearance language | "Lift" (brow, neck, submental) | "Lift" (brow, submental, neck); "improve lines/wrinkles" | "Treatment of wrinkles/rhytids" |
| Discomfort | High | Low–moderate | Moderate |
| Treatment time | 45–90 min | 30–45 min | 45–90 min |
| Face cost | $2,500–$4,500 | $2,000–$4,000 | $1,500–$3,500 |
| Body areas | Arms, abdomen (PRIME 2025) | Upper arms, cellulite, acne scars | Face, eyes, body, cellulite |
| Evidence base | Largest (120+ publications) | Growing (newer device) | Long-established (20+ years) |
Risks worth knowing
Ultherapy: The 4.5 mm transducer reaches the subcutaneous fat layer. If energy is misdirected — particularly by an inexperienced provider — it can cause focal fat atrophy, creating a hollowed or deflated appearance that is difficult to correct. This is a recognized, if uncommon, complication. Ultherapy's real-time visualization is meant to mitigate this risk by allowing the provider to confirm tissue depth before firing, but visualization is only as good as the person interpreting the image. Transient nerve effects (tingling, numbness) are also reported and typically resolve within days to weeks.
Sofwave: Fixed 1.5 mm depth keeps energy within the dermis and away from fat and nerves. This makes the safety profile more forgiving, but it also means Sofwave cannot address deeper structural laxity. Mild redness and tenderness for a few hours post-treatment are the most common side effects.
Thermage: Volumetric RF heating is generally well-tolerated. Rare surface irregularities have been reported. The monopolar circuit requires a return electrode pad, which must have good skin contact to avoid localized burns. The RF energy penetrates broadly, which is efficient for coverage but means less control over exactly where heat concentrates compared to focused ultrasound.
Who will be disappointed
The single most important thing to understand about all three devices: none of them replaces a surgical facelift for significant laxity. If a patient has jowling that has collapsed the jawline, deep nasolabial folds, or substantial neck banding, non-surgical tightening will produce marginal improvement at best.
Patients most likely to see meaningful results:
- Mild to moderate skin laxity
- Early signs of aging (30s–50s)
- Realistic expectations about incremental improvement
- Willing to wait 3–6 months for full results
Patients most likely to be disappointed:
- Significant ptosis (sagging) that would clearly benefit from surgery
- Expecting a "non-surgical facelift" with dramatic before/after change
- Advanced skin laxity in the 60+ age range where collagen response is diminished
- Patients who have already had minimal results from one round and expect a different outcome from repeating the same treatment
The distinction between Ultherapy's "lift" clearance and Thermage's "wrinkle treatment" clearance matters more for marketing language than for the patient experience. Both tighten skin through collagen stimulation. The real differentiator is Ultherapy's ability to reach the SMAS layer and its real-time imaging, which allows more targeted energy delivery — but the clinical significance of SMAS targeting in a non-surgical context remains debated.
What about combination approaches?
Some practices offer staged treatments: Ultherapy for deeper structural correction, Sofwave for mid-dermal skin quality, or Thermage for broader surface tightening. There is no strong evidence that combining these in the same session produces additive results proportional to the added cost. Sequential use — completing one modality's full course and reassessing — is more conservative and avoids compounding thermal injury.
RF microneedling (e.g., Morpheus8, which is covered separately on this site) is sometimes positioned alongside these devices for patients who want both tightening and texture improvement. RF microneedling penetrates the dermis with insulated needles and delivers RF energy at the needle tip, combining mechanical injury with thermal stimulation. It addresses different concerns (texture, acne scars, pores) and is complementary rather than interchangeable with ultrasound/RF skin tightening.
Questions to ask a provider
- What specific clearance language applies to the treatment you are recommending — is it "lifting," "tightening," or "wrinkle treatment"?
- How do you select between Ultherapy, Sofwave, and Thermage for a patient like me?
- How many of these treatments have you performed, and what is your reassessment protocol if results are minimal after 6 months?
- What is the total cost for the number of sessions you recommend, and what happens if I need more?
- At what point would you recommend I consider a surgical consultation instead?
Sources
- Merz Aesthetics. Ultherapy PRIME product information and FDA clearance history. https://ultherapy.com/physicians/innovating-aesthetics
- Merz Aesthetics. Ultherapy PRIME FDA clearance for arms and abdomen (November 2025). https://merzaesthetics.com/news/merz-announces-new-arms-abdomen-indication-ultherapy/
- FDA 510(k) K170758 — Thermage FLX System, Solta Medical, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/K170758.pdf
- Solta Medical. Thermage FLX product information. https://www.soltamedicalus.com/
- FDA 510(k) K211483 — SofWave System, Sofwave Medical, 2021. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211483.pdf
- FDA 510(k) K240687 — SofWave System, Sofwave Medical, 2024. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf24/K240687.pdf
- Sofwave Medical. Sofwave SUPERB technology product information. https://sofwave.com/
- A systematic review of the clinical efficacy of micro-focused ultrasound treatment for skin rejuvenation and tightening. PMC, 2022. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8722640/
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Marquardt K, et al. Microfocused ultrasound with visualization induces remodeling of collagen and elastin within the skin. J Cosmet Dermatol. 2025;24(7):e76638.
